FDA RAG-17 coverage for business development, investment, and market access teams
Latest on RAG-17
Ractigen Therapeutics RAG-17 Shows 81% Reduction in ALS Biomarker in Phase I Trial
Ractigen's RAG-17 demonstrates 81% reduction in neurofilament light chain biomarker in SOD1-ALS patients with single intrathecal dose in Phase I trial.
Ractigen Therapeutics RAG-17 Shows 81% Reduction in ALS Biomarker in Phase I Trial
Ractigen's RAG-17 siRNA therapy demonstrates 81% reduction in neurofilament light chain and clinical stabilization trends in SOD1-ALS patients at AAN 2026.